Ionis Pharmaceuticals Announces New Data for TRYNGOLZA, Reports Strong Q2 Revenue
On August 20, Ionis Pharmaceuticals (IONS) announced it will present new cardiometabolic data on its FDA-approved drug TRYNGOLZA and investigational siRNA ION775 at the European Society of Cardiology Congress in Munich. The Phase 3 extension results showed sustained triglyceride reductions and a significant drop in acute pancreatitis events, reinforcing clinical potential. In Q2 2026, Ionis reported total revenue of $268 million, surpassing estimates of $194.5 million. Commercial product sales reached $119 million with early U.S. revenues from DAWNZERA and TRYNGOLZA contributing significantly. The company also maintained a strong cash position of $2.05 billion in short-term investments. Investors are evaluating whether Ionis can transition into an independent, profitable commercial entity rather than remaining R&D-focused. While the bull case highlights clinical success and recurring royalty potential from its RNA pipeline, bears point to ongoing losses and financial risks.
Tickers: $IONS
Topics: commercial pipeline DAWNZERA Ionis Pharmaceuticals revenue report TRYNGOLZA